Ratios

		vs industry	vs history
P/B	2.29	ERB's P/B is ranked higher than 53% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.41 vs. ERB: 2.29 )	ERB' s 10-Year P/B Range Min: 0.46   Max: 7.03 Current: 2.29 0.46 7.03
P/S	1.70	ERB's P/S is ranked higher than 65% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.40 vs. ERB: 1.70 )	ERB' s 10-Year P/S Range Min: 0.42   Max: 43.25 Current: 1.7 0.42 43.25
EV-to-EBIT	-70.77	ERB's EV-to-EBIT is ranked lower than 71% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 16.12 vs. ERB: -70.77 )	ERB' s 10-Year EV-to-EBIT Range Min: 18.2   Max: 338.2 Current: -70.77 18.2 338.2

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	4	ERB's Price/Net Current Asset Value is ranked lower than 61% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 12.40 vs. ERB: 4 )	ERB' s 10-Year Price/Net Current Asset Value Range Min: 2   Max: 20.5 Current: 4 2 20.5
Price/Tangible Book	2.5	ERB's Price/Tangible Book is ranked higher than 51% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 4.80 vs. ERB: 2.5 )	ERB' s 10-Year Price/Tangible Book Range Min: 0.9   Max: 4.9 Current: 2.5 0.9 4.9
Price/Median PS Value	0.9	ERB's Price/Median PS Value is ranked higher than 65% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 0.90 vs. ERB: 0.9 )	ERB' s 10-Year Price/Median PS Value Range Min: 0.4   Max: 5.6 Current: 0.9 0.4 5.6
Forward Rate of Return (Yacktman)	-7.29	ERB's Forward Rate of Return (Yacktman) is ranked higher than 52% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 8.11 vs. ERB: -7.29 )	ERB' s 10-Year Forward Rate of Return (Yacktman) Range Min: -10.2   Max: -4.9 Current: -7.29 -10.2 -4.9

Business Description

ERBA Diagnostics Inc was incorporated on June 28, 1999 under the laws of the State of Delaware. It is the parent corporation of the following three subsidiaries: elta Biologicals, S.r.l.; Diamedix Corporation; and ImmunoVision, Inc. Through these subsidiaries, it develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune and infectious diseases. These tests, which are designed to aid in the identification of the causes of illness and disease, assist physicians in selecting appropriate patient treatment. Its tests are based on Enzyme Linked ImmunoSorbent Assay, or ELISA, technology, a clinical testing methodology used worldwide. Specific tests are prepared using a 96 well microplate format whereby specific antigens are typically coated on the wells of a microplate during the manufacturing process. A test using ELISA technology involves a series of reagent additions to the microplate causing a reaction that result in a visible color in the wells. The amount of color is directly proportionate to the amount of the specific analyte in the patient sample. Its kits are designed to be performed either manually or in an automated format. In addition to its line of diagnostic kits, it also designs and manufactures laboratory instruments that perform the tests and provide fast and accurate results, while reducing labor costs. Its existing proprietary instruments, named the Mago 4, Mago 4S, Mago Plus and Aptus systems, include a fully-automated ELISA processor operating with its own user-friendly software, which allows customers to perform tests in an automated mode. In 2009, it updated the Mago Plus instrument to include the capability to process ELISA and ImmunoFluorescent Assay, or IFA, simultaneously. In the fourth quarter of 2009, it completed the development of, received European regulatory approvals for, and began non-domestic commercial deliveries of, an upgraded version of the Mago Plus instrument, named the Mago 4, which performs both ELISA and IFA techniques simultaneously, performs positive sample identification and utilizes disposable pipette tips. The Mago 4 offers an enhanced automation solution to customers who prefer a more compact, lower-priced instrument with features and benefits similar to many of the other instruments currently offered in the marketplace. In 2010, it continued the development of a variation of the Mago Plus, named the Mago 4S, for the market in the United States. The Mago 4S also performs both ELISA and IFA techniques simultaneously. In January 2011, it received the required 510(k) regulatory clearance for the Mago 4S and, later in 2011; it began to market the instrument in the United States. It also develops, manufactures and markets raw materials, such as antigens used in the production of diagnostic kits. The testing, manufacturing and sale of its products are subject to regula
Company Website
SEC Reports

Industry:	Medical Instruments & Supplies
Compare:	BIO, VIVO, TRIB, TMO, IMA, KOOL

» More Articles for ERB

Headlines

Articles On GuruFocus.com

Personalized Checklist